Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00266721 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Pancrelipase on Postprandial Belching and Bloating.
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
NCT00266721 is a Phase 3 study that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 45 participants.
The verdict
NCT00266721, a Phase 3 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
Study Summary
The hypothesis of this study is that the administration of pancrelipase with meals will benefit symptoms of post-prandial bloating, pain and eructation.
Interventions
- DRUG Pancrelipase (Creon) 2 tablets with each meal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2000-01 |
| Est. Completion | 2000-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00266721
The ClinicalTrials.gov registry entry for NCT00266721 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pancrelipase (Creon) 2 tablets with each meal is the first listed.
NCT00266721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00266721 about?
NCT00266721 is a clinical study titled "Efficacy of Pancrelipase on Postprandial Belching and Bloating.". The hypothesis of this study is that the administration of pancrelipase with meals will benefit symptoms of post-prandial bloating, pain and eructation.
What is the current status of trial NCT00266721?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2000-01. Estimated completion is 2000-10.
What interventions are being tested in trial NCT00266721?
The interventions under investigation include: Pancrelipase (Creon) 2 tablets with each meal (DRUG).
Who is sponsoring clinical trial NCT00266721?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.